The Patent Finder

Laimu Corporation

9 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 19, 2027
    The maintenance fee for Method for improving eye conditions (US 11,759,483) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same (US 11,911,417) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

PatentTitleStatus Expires Confidence
US 10,973,858Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,911,417Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,345,675Compound, anti-allergy drug, and mediator release inhibitor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,179,414Method for producing protease degradation composition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,246,849Nerve growth promoter
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,110,501Neurogenesis Stimulant, Internal Agent, Culture Medium Additive, Cell Diluent Additive, Culture Medium, and Cell Diluent
In force
 · High confidence
In forceHigh confidence
US 11,564,950Composition and method for producing the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,759,483Method for improving eye conditions
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,622,933Method for Improving Eye Condition
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

Every application published under this name has become a patent.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited